176 completed, 36 unknown, 23 recruiting, 15 active not recruiting. 65 Phase 1, 64 Phase 2, 47 Not applicable, 33 Phase 3, 3 Early Phase 1.
Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue | Not yet recruiting | Liverpool School of Tropical Medicine | 235 | 2026-11-01 | 2026-09-02 | |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever | Recruiting | University of Oxford | 190 | 2026-08-01 | 2026-08-06 | |
| Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya | Not applicable | Not yet recruiting | Universidade do Estado do Pará | 54 | 2026-07-01 | 2026-05-26 |
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue | Phase 2 / Phase 3 | Recruiting | Hyundai Bioscience Co., Ltd. | 210 | 2026-04-09 | 2026-07-10 |
| Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities Full intervention, Partial intervention - Dengue, Zika | Not applicable | Completed | University of Freiburg | 900 | 2026-03-26 | 2026-04-08 |
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) Resomelagon, Placebo, Standard Treatment - Dengue Fever | Phase 2 | Recruiting | Federal University of Minas Gerais | 120 | 2026-03-20 | 2026-09-15 |
| Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam Dengue | Active not recruiting | Tam Anh Research Institute | 800000 | 2026-03-16 | 2026-04-13 | |
| A Controlled Human Infection Model of Dengue GMP-produced rDEN3delta30 virus - Dengue | Not applicable | Active not recruiting | Tan Tock Seng Hospital | 5 | 2026-03-05 | 2026-10-16 |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) Dengue 1,2,3,4 (attenuated) vaccine - Dengue | Phase 3 | Active not recruiting | Butantan Institute | 997 | 2026-03-03 | 2026-11-10 |
| Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital Objective 1- economic evaluation of Thai children with dengue vaccine - Dengue Fever | Active not recruiting | Mahidol University | 350 | 2026-02-02 | 2026-08-17 | |
| A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) TDV, Placebo - Dengue Fever | Phase 3 | Active not recruiting | Takeda | 800 | 2026-01-20 | 2026-09-22 |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR) Dengue Disease, Dengue Haemorrhagic Fever | Recruiting | Mahidol University | 100 | 2025-12-01 | 2026-02-17 |
Showing 20 of 282. Sign in to see all of them.
Severe Dengue (65) · Chikungunya Fever (31) · Zika Virus Infection (25) · Virus Diseases (12) · Arbovirus Infections (11) · Malaria (10) · Flavivirus Infections (8) · Fever (7) · Hemorrhagic Fevers, Viral (7) · Vector Borne Diseases (6) · Yellow Fever (4) · Communicable Diseases (3) · Influenza, Human (3) · Mosquito-Borne Diseases (3)
Flaviviridae Infections (280) · Infections (280) · Mosquito-Borne Diseases (279) · RNA Virus Infections (279) · Vector Borne Diseases (276) · Hemorrhagic Fevers, Viral (275) · Flavivirus Infections (274) · Arbovirus Infections (271) · Virus Diseases (270) · Alphavirus Infections (31) · Togaviridae Infections (31) · Pathological Conditions, Signs and Symptoms (27) · Pathologic Processes (18) · Parasitic Diseases (10) · Protozoan Infections (10)
Dengue Vaccines (14) · Vaccines (12) · Sodium Chloride (9) · Blood Specimen Collection (7) · Aluminum Hydroxide (5) · Data Collection (5) · AT-752 (3) · Biological Products (3) · Measles-Mumps-Rubella Vaccine (3) · Solutions (3) · Urination (3) · adacel (3) · ChimeriVax (2) · Dexamethasone (2) · Dosage Forms (2)
National Institute of Allergy and Infectious Diseases (NIAID) (37) · Sanofi Pasteur, a Sanofi Company (30) · Takeda (17) · U.S. Army Medical Research and Development Command (15) · Mahidol University (7) · Sanofi (6) · Butantan Institute (5) · GlaxoSmithKline (5) · Oxford University Clinical Research Unit, Vietnam (5) · Institut Pasteur (4) · Atea Pharmaceuticals, Inc. (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (3) · Centre Hospitalier Universitaire de la Réunion (3) · Foundation for Innovative New Diagnostics, Switzerland (3) · Kaohsiung Medical University Chung-Ho Memorial Hospital (3)
United States (69) · Thailand (32) · Brazil (26) · Colombia (22) · Malaysia (20) · Mexico (19) · Vietnam (16) · Singapore (15) · Philippines (13) · Indonesia (11) · Bangladesh (10) · France (8) · Puerto Rico (8) · Cambodia (7) · Peru (7)
Anna Durbin, MD (26) · Beth Kirkpatrick, MD (4) · Kristen Pierce, MD (3) · Myrielle Dupont-Rouzeyrol, PhD (3) · Stephen J Thomas, MD (3) · Fernanda C Boulos, MD, PhD (2) · Jacqueline L. Deen, MD (2)
PMID 40099800, PMID 42253092, PMID 26214039, PMID 29897841, PMID 33822015, PMID 26383952, PMID 39116904, PMID 23563266, PMID 25801652, PMID 26424605, PMID 26458804, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 31878895, PMID 32220283, PMID 32394880, PMID 32572470, PMID 32932330, PMID 33212068, PMID 33422034, PMID 34003796, PMID 34107180, PMID 34219653, PMID 35659904, PMID 36057771, PMID 37254133, PMID 37971871, PMID 38294972, PMID 39308445, PMID 39356094, PMID 42480195, PMID 15272410, PMID 15577938, PMID 16269927, PMID 16603571, PMID 18337339, PMID 19292665, PMID 19822889, PMID 19859541, PMID 21111785, PMID 21208923, PMID 21813857, PMID 21976579, PMID 22807519, PMID 22863660, PMID 22894958, PMID 22975340
2014 (6), 2019 (3), 2018 (2), 2023 (2), U01AI148069 (1)